BioMarin Pharmaceutical Inc. (BMRN) Price Target Lowered to $105.00 at Stifel Nicolaus

Cornelia Mascio
Novembre 14, 2017

Over the past 50 days, BioMarin Pharmaceutical Inc. stock was -16.18% off of the high and -0.11% removed from the low. The stock declined 0.13% or $0.22 reaching $172.13 per share. About shares traded. BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical had 73 analyst reports since August 5, 2015 according to SRatingsIntel. It has underperformed by 11.41% the S&P500. Invesco holds 0.12% of its portfolio in BioMarin Pharmaceutical Inc. Jefferies Group LLC restated a "buy" rating and issued a $116.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 26th. The stock decreased 7.62% or $0.037 on November 10, reaching $0.45. The Zevenbergen Capital Investments Llc holds 283,685 shares with $25.76M value, down from 310,359 last quarter. Hartford Investment Management Co. raised its position in BioMarin Pharmaceutical by 2.5% in the second quarter. (BMRN) lately? The stock closed the regular trading session at $81.06 yesterday, compared to the closing price of $82.03 the previous day - a change of -1.18 percent. (NASDAQ:BMRN). Weiss Multi has 0.17% invested in BioMarin Pharmaceutical Inc. It has underperformed by 16.70% the S&P500. This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell. $451,164 worth of Amgen, Inc.

Analysts await Amgen, Inc. Sg Americas Securities Ltd Llc reported 1,933 shares. T_IRG's profit would be $3.63M giving it 17.29 P/E if the $0.06 EPS is correct. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. Quintiles Transnational had 59 analyst reports since July 22, 2015 according to SRatingsIntel. Therefore 29% are positive. Citigroup maintained the stock with "Sell" rating in Monday, November 6 report. Mizuho initiated the shares of AMGN in report on Tuesday, November 8 with "Buy" rating. The consensus recommendation rating is a Moderate Buy. The firm earned "Buy" rating on Wednesday, October 5 by UBS. Bernstein maintained Amgen, Inc. The stock has "Buy" rating by Jefferies on Sunday, August 27. BMO Capital Markets maintained it with "Buy" rating and $11700 target in Friday, July 21 report. The stock of Cobalt International Energy, Inc. The stock of Iqvia Holdings Inc (NYSE:Q) has "Neutral" rating given on Monday, March 28 by SunTrust.

Investors sentiment increased to 0.93 in 2017 Q2. Its up 0.06, from 1.2 in 2017Q1. It dropped, as 72 investors sold AMGN shares while 463 reduced holdings. Waddell And Reed Fincl Inc reported 1.14 million shares. Its up 8.04% from 5.64M shares previously. Klingenstein Fields Ltd holds 0.02% or 2,692 shares in its portfolio. Deutsche Bank AG reissued a "buy" rating and issued a $119.00 price target (up from $118.00) on shares of BioMarin Pharmaceutical in a report on Wednesday, August 9th. (NASDAQ:AMGN) for 82,136 shares. Quantitative Invest Mgmt Limited Liability Company stated it has 13,800 shares. Bain Cap Public Equity Mngmt Ltd Liability Corporation has invested 2.89% in Iqvia Holdings Inc (NYSE:Q). (NASDAQ:AMGN). Calamos Advsr Limited Com reported 0.29% of its portfolio in Amgen, Inc. (NASDAQ:BMRN) to report earnings on February, 22. Nomura has invested 0.04% in Amgen, Inc. Nordea Invest Management Ab invested in 0.02% or 102,465 shares. Oppenheimer Asset holds 9,300 shares or 0.02% of its portfolio. Thomas J Herzfeld Advisors holds 0.02% or 400 shares.

Investors sentiment increased to 1.26 in Q2 2017. Its up 0.11, from 0.82 in 2017Q1. (BMRN) is CAPITAL RESEARCH GLOBAL INVESTORS, which now holds 18,898,699 shares. 51 funds opened positions while 134 raised stakes. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company's stock worth $1,202,709,000 after purchasing an additional 3,348,168 shares during the period. Cibc Asset Mngmt has invested 0.01% in BioMarin Pharmaceutical Inc.

The total number of shares of a company owned out there (shares owned by institutional investors, insiders and officers included) are called the company's "shares outstanding". Legal And General Grp Public Limited Company reported 721,398 shares or 0.05% of all its holdings. Platinum Inv Mngmt Ltd owns 13,820 shares for 0.03% of their portfolio. Following the completion of the sale, the executive vice president now owns 41,342 shares in the company, valued at approximately $3,952,708.62. (NASDAQ:BMRN). Howe And Rusling, New York-based fund reported 83 shares. Ohio-based Keybank Natl Association Oh has invested 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Cibc Mkts stated it has 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Proshare Advisors Ltd has 143,073 shares. Two Sigma Limited Co holds 0.19% or 10,786 shares in its portfolio. Old Mutual Customised Solutions (Proprietary) reported 0.07% in BioMarin Pharmaceutical Inc. Cowen & Co maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 976 shares. They expect $-0.25 EPS, up 32.43% or $0.12 from last year's $-0.37 per share. After $-0.07 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 257.14 % negative EPS growth. It also upped Shopify Inc. stake by 222,240 shares and now owns 837,955 shares. Manitowoc Inc (NYSE:MTW) was raised too.

Since May 17, 2017, it had 0 buys, and 8 selling transactions for $5.08 million activity. (NASDAQ:BMRN) was sold by BIENAIME JEAN JACQUES. The insider LAWLIS V BRYAN sold 3,750 shares worth $337,500. Shares for $89,968 were sold by Ajer Jeffrey Robert on Wednesday, June 7. LAWLIS V BRYAN also sold $337,500 worth of BioMarin Pharmaceutical Inc. Therefore 70% are positive. (NYSE:CIE) on Friday, May 5 to "Market Perform" rating. (NASDAQ:BMRN) has "Buy" rating given on Tuesday, August 25 by Cowen & Co. The stock has "Neutral" rating by Wedbush on Tuesday, September 1. The firm has "Hold" rating by Zacks given on Friday, September 4. Davis George Eric sold $862,230 worth of BioMarin Pharmaceutical Inc. Leerink Swann has "Buy" rating and $142.0 target. The rating was initiated by BMO Capital Markets on Thursday, April 7 with "Outperform". The firm has "Outperform" rating by William Blair given on Friday, August 4.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE